Cell Therapies names new CEO
Melbourne-based cellular therapy manufacturer and distributor Cell Therapies has appointed Dr Tim Oldham as its new CEO.
Oldham has more than a decade of experience in the life science sector, having held various positions including president of Asia-Pacific for Hospira and a series of senior management roles at Mayne Pharma. He is currently a director of Acrux (ASX:ACR) and iSonea (ASX:ISN).
Oldham is replacing founding CEO and managing director Ray Wood, who will continue on as a director.
Announcing the appointment, Cell Therapies said Oldham has been selected to implement the company’s aggressive growth plan.
“As late-stage and improved product numbers grow, scaling manufacturing up and out to reliably deliver a time-sensitive, patient-specific product with needle-to-needle control is becoming the challenge facing the cell-based therapies industry,” Oldham said.
“Cell Therapies’ unique expertise is solving this challenge. I am very excited to have been chosen to build on this expertise and grow our contract manufacturing and approved product distribution business into South-East Asia.”
The company is in talks to acquire distribution rights to a number of late-stage products, is upgrading its Melbourne manufacturing capacity and is in talks with a partner to develop a new facility in Malaysia.
The company licensed a second-generation cartilage repair product from Medipost in January 2013.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
